Obesity is a major public health problem worldwide and an established risk factor for cardiovascular disease. In individuals with obesity or overweight, systemic inflammation and endothelial dysfunction contribute to myocardial hypertrophy, ventricular remodeling, and alterations in cardiac morphology and function. Weight loss has been shown to improve metabolic and hemodynamic parameters; however, evidence regarding structural and functional cardiac reversibility remains limited. This prospective single-center cohort study aims to evaluate changes in cardiac morphology and function (assessed by cardiac magnetic resonance imaging and echocardiography), as well as changes in inflammatory and cardiac biomarkers, in patients with obesity or overweight and cardiovascular risk factors who achieve at least a 10% reduction in body weight through pharmacological or non-pharmacological interventions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Left Ventricular Mass by Cardiac MRI
Timeframe: Baseline, 3 months, 6 months, and 9 months.
Right Ventricular Mass by Cardiac MRI
Timeframe: Baseline, 3 months, 6 months, and 9 months.
Left Ventricular Ejection Fraction
Timeframe: Baseline, 3 months, 6 months, and 9 months.
Right Ventricular Ejection Fraction
Timeframe: Baseline, 3 months, 6 months, and 9 months.
Diastolic Function Left Ventricle
Timeframe: Baseline, 3 months, 6 months, and 9 months.
Diastolic Function Right Ventricle
Timeframe: Baseline, 3 months, 6 months, 9 months.